New Positive Allosteric Modulators Of Nicotinic Acetylcholine Receptors For Treatment Of Cognitive Impairment In ADHD
Funder
National Health and Medical Research Council
Funding Amount
$612,851.00
Summary
The effects of Attention Deficit Hyperactivity Disorder (ADHD) can extend well beyond childhood. This project will target the nicotinic acetylcholine receptor family for developing new therapeutics to manage this disease.
The Role Of Neuronal Nicotinic Receptor Subunits In The Self-Administration And Relapse To Alcohol Seeking:Treatments For Alcohol Dependence
Funder
National Health and Medical Research Council
Funding Amount
$531,787.00
Summary
The World Health Organization reports that alcohol causes almost two million deaths every year and results in physical disability or shortened life span for at least 58 million others. Despite the fact that addiction represents more than 40% of brain-related illnesses, there is a dearth of innovative treatments. The overall goal of my research is to develop more effective medications for the treatment of alcohol use disorder by targeting the neuronal nicotinic receptor subtypes that have been sp ....The World Health Organization reports that alcohol causes almost two million deaths every year and results in physical disability or shortened life span for at least 58 million others. Despite the fact that addiction represents more than 40% of brain-related illnesses, there is a dearth of innovative treatments. The overall goal of my research is to develop more effective medications for the treatment of alcohol use disorder by targeting the neuronal nicotinic receptor subtypes that have been specifically altered by heavy alcohol intake.Read moreRead less
An Investigation Into The Molecular Basis Of MAIT Cell Recognition Of Vitamin B Based Metabolites
Funder
National Health and Medical Research Council
Funding Amount
$883,762.00
Summary
Mucosal associated invariant T cells (MAIT cells) are an abundant T-cell population in humans, that is found mostly in the gastrointestinal mucosa. We have recently shown that MAIT cells can be activated by metabolites of vitamin B. This proposal will investigate how the MAIT cells "see" vitamin B metabolites. This research will pave the way for novel therapeutics that can modulate MAIT cell activity.
KYNURENINE PATHWAY METABOLOMIC PROFILING IN THE PROGRESSION OF MULTIPLE SCLEROSIS: DEVELOPMENT OF NOVEL BIOMARKER TO ASSESS DISEASE SEVERITY AND THERAPEUTIC REGIMEN
Funder
National Health and Medical Research Council
Funding Amount
$450,750.00
Summary
A metabolic process known as the kynurenine pathway (KP) has been found to be dysregulated in multiple sclerosis (MS) patients. We are currently investigating which components of the KP is impaired that put MS patients in jeopardy. Next, we aim to use specific drugs known to manipulate the KP in order to rectify the impairment and stop MS. Outcome of this study may potentially lead to discovery of new biomarkers to assess severity of MS progression and also novel therapeutic regimen.
Neuregulin 1 Type III Overexpression And Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$651,966.00
Summary
Neuregulin (NRG1) is a neuronal growth factor and regulates the development of cortical inhibitory interneurons. Human studies suggest that NRG1 type III overexpression and deficient interneuron development underlie schizophrenia. Thus, we have developed a mouse overexpressing Nrg1 type III to discover mechanisms behind NRG1-related cortical pathology and schizophrenia-like behaviours and to clarify whether NRG1 type III interacts with environmental risk factors for the disorder.
The Involvement Of The Kynurenine Pathway In Blood Brain Barrier Disruption And Its Relevance For Neuroinflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$597,797.00
Summary
We aim to study the involvement of molecules deriving from the degradation of the essential amino acid tryptophan on the breakdown of the ñblood-brain barrierî (the cellular wall separating blood and brain) that is observed in several major brain diseases. Using specific drugs blocking the production or the effects of these toxic compounds we expect to be able to preserve the integrity of the blood brain barrier and so to limit brain inflammation and neuronal loss.
Extracellular Acidification And Its Role In Disease
Funder
National Health and Medical Research Council
Funding Amount
$371,529.00
Summary
This proposal focuses on the diseases cystic fibrosis and acute pancreatitis for which there are currently no treatments. In both diseases the affected organs become strongly acidic. Furthermore, these acid changes can be causal in disease progression. However, the source of this acidification is remains unknown. We will identify the routes of acid secretion, the causal role of acidification in disease progression and the effectiveness of treatments aimed at restoring acid-base balance.
Pharmacological Development Of A Stable Cytochrome P450-mediated Omega-3 Fatty Acid Epoxide Analogue As A Novel Anti-metastatic Agent
Funder
National Health and Medical Research Council
Funding Amount
$599,847.00
Summary
Dietary ?-3 fatty acids decrease the risk of cancer metastasis. We have found that a certain ?-3 fatty acid metabolite inhibits tumour cell migration but is too unstable to be a useful drug. We have now prepared a stable version of this metabolite for in vivo use as a potential anti-metastatic drug. In this project we will define the mechanism of action of this novel agent and evaluate how it may be best used in patient treatments by testing in a range of in vivo animal models of metastasis.
Using Artificial Synapses To Investigate The Functional Pathology Underlying Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$515,256.00
Summary
Epilepsy is a common neurological disorder. Some forms arise from hereditary mutations to GABA-A receptors. To advance our understanding of epileptogenesis, it is necessary to understand how mutations affect GABA-AR function. We will use a novel ‘artificial synapse’ system to characterise these mutant receptors. This will define how epilepsy is caused and inform us how to best tailor drug treatments for different epilepsy conditions.
Oxytocin As A Novel Antagonist Of The Intoxicating And Addictive Effects Of Alcohol
Funder
National Health and Medical Research Council
Funding Amount
$739,106.00
Summary
Alcohol is Australia’s most harmful recreational drug and more effective treatments for alcohol abuse are desperately needed. The CIs have shown that administering oxytocin reduces alcohol intoxication and consumption, and prevents alcohol from acting at specific sites in the brain that are central to alcohol’s intoxicating and addictive effects. This project probes the effects of oxytocin at these sites and the potential utility of targeting this interaction to treat alcohol-use disorders.